Anti-Cancer Drugs

Our screening does not flag Anti-Cancer Drugs. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in Scopus, Web of Science, PubMed, which is a positive signal.

Per our venue index, Anti-Cancer Drugs appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.

Papers in Anti-Cancer Drugs are cited about 2.1 times each within two years of publication, and Scimago places it in Q3, with an h-index of 115. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.

In the Scimago Journal Rank 2025 edition, Anti-Cancer Drugs is Q3 in 3 of its 4 subject categories and Q4 in the other 1. By category: Pharmacology (medical): Q3, #162 of 286; Pharmacology: Q3, #195 of 339; Oncology: Q3, #274 of 426; Cancer Research: Q4, #186 of 235. Its best category quartile is Q3. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Anti-Cancer Drugs is cited about 2.1 times per paper over two years, with an h-index of 115.

The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Anti-Cancer Drugs. The open equivalent is its best Scimago quartile, Q3 in Pharmacology (medical) and 2 other categories, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.

Our index records its access status as "hybrid". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.